Sanfetrinem, przedstawiciel trinemow - aktywnosc in vitro wobec szczepow Klebsiella pneumoniae wytwarzajacych ESBL

• Autorzy: Wieczorek P. , Sacha P.T. , Leszczynska K. , Jakoniuk P. , Zalewska M.

Warianty tytułu

EN

Sanfetrinem, the member of trinems - in vitro activity against Klebsiella pneumoniae producing ESBL

• Języki publikacji: PL

Abstrakty

PL

Zbadano wrażliwość 43 szczepów Klebsiella pneumoniae wytwarzających ESBL wobec sanfetrinemu. Uzyskane wyniki porównano z wynikami dla imi- penemu (MIC50, MIC90). Wszystkie izolaty były wrażliwe na imipenem i cefe- pim, a oporne na gentamycynę, amikacynę i trimetoprim/sulfametoksazol.

EN

Sanfetrinem is the first member of tricyclic ß-!actams (trinems) which can be administered orally as a hexatil ester. His chemical structure is related to carbapenems. High stability to many ß-lactamases and human renal dehydropeptydase were described. The investigation was performed on 43 strains of Klebsiella pneumoniae producing ESBL isolated from hospitalized patients. The MICs of sanfetrinem and imipenem were determined by E-test. Additio- naly, susceptibility to antibiotics was tested by disc diffusion method. Klebsiella pneumoniae ATCC 700603, Escherichia coli ATCC 25922 and Escherichia coli ATCC 35218 were used as a control strains. MIC50 and MIC90 of sanfetrinem and imipenem amounted respectively 0,38/3 mg/l and 0,19/0,25 mg/l. Range of MIC value was from 0,064 mg/l to 4 mg/l for sanfetrinem, and from 0,094 mg/l to 0,38 mg/l for imipenem. Additionaly, geometric and aritmetic means were calculated to both antibiotics. All results of study were compared using correlation factor and „Student" t-test. None of these 43 Klebsiella pneumoniae strains was resistant to imipenem and cefepime. Majority of isolates demonstrated susceptibility to ciprofloxacin and cefoxitin - 90,7% and 74,4% respectively. All strains were resistant to gentamicin, amikacin and trimethoprim/sulfamethoxazole.

Słowa kluczowe

PL

antybiotyki beta-laktamowe; trinemy; sanfetrinem; aktywnosc antybakteryjna; Klebsiella pneumoniae; wrazliwosc na antybiotyki

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2006
• Tom: 58
• Numer: 1
• Opis fizyczny: s.27-32,rys.,tab.,bibliogr.

Twórcy

autor

Wieczorek P.

• Akademia Medyczna w Bialymstoku, ul.Waszyngtona 15A, 15-274 Bialystok

autor

Sacha P.T.

autor

Leszczynska K.

autor

Jakoniuk P.

autor

Zalewska M.

Bibliografia

• 1. Andrews JM, Hadley N, Brenwald NP i inni. Susceptibility testing of fastidious organisms. J Antimicrob Chemother 1997, 39: 436-7.
• 2. Babini GS, Yuan M, Livermore DM. Interaction of beta-lactamases with sanfetrinem (GV 104326) compare to those with imipenem and with oral beta-lactams. Antimicrob Agents Chemother 1998; 42: 1168-75.
• 3. Betritt C, Gomez M, Palau ML i inni. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Antimicrob Agents Chemother 1999; 43: 2320-2.
• 4. Chen HY,Livermore DM. Comparative activity of cefepime against chromosomal ß-lactamase inducibility mutants of gram-negative bacteria. J Antimicrob Chemother 1993; 32: Suppl. В 63-74.
• 5. Doern GV, Pierce G, Brueggemann AB. In vitro activity of sanfetrinem (GV 104326), a newtrinem antimicrobial agent, versus Streptococcus pneumoniae, Hemophilus influenzae, and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1996; 26: 39 -42.
• 6. Edwards JR, Betts MJ. Carbapenems: the pinnacle of the ß-lactam antibiotics or room for improvement. J Antimicrob Chemother 2000; 45: 1-4.
• 7. Efihymiopoulos CA, Capriati A, Barrington P i inni. Pharmacokinetics of GV 104326, a novel tribactam antibiotic, following single intravenous and oral (as its prodrug GV 118819X) administration in man [abstract F82], In abstracts of the 34"' Interscience Conference on Antimicrobial Agents and Chemotherapy: American Society for Microbiology. Washington, DC, 1994; 129.
• 8. Iavarone L, Bottacini M, Pugnaghi F i inni. Sanfetrinem and sanfetrinem-cilexetil: disposition in rat and dog. Xenobiotica 1997; 7: 693 -709.
• 9. Jarlier V, Nicolas M, Fournier G i inni. Extended broad - spectrum ß-lactamases conferring transferable resistance to agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-78.
• 10. Johnson АР, Warner M, Speller DC. In-vitro activity of sanfetrinemagainst isolates of Streptococcus pneumoniae and Staphylococcus aureus. J Antimicrob Chemother 1998; 42: 643-6.
• 11. Kita Y, Yamazaki T, Imada A i inni. Disposition of cyclohexyl-carbonyloxyethyl side chain from Cefotiam Hexetil in mice: metabolism of acetaldehyde. Japan Pharmacol and Therap 1988; 16: 131-5.
• 12. Modugno ED, Broggio R, Erbetti I i inni. In vitro and in vivo antibacterial activities of GV 129606, a new broad-spectrum trinem. Antimicrob Agents Chemother 1997; 41: 2742-8.
• 13. Modugno ED, Erbetti I, Ferrari L i inni. In vitro activity of the tribactam GV 129606 against Gram- positive, Gram-negative, and anaerobic bacteria. Antimicrob Agents Chemother 1994; 38: 2362-8.
• 14. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. 7"' ed. Approved stadard M2 - A7 (M100 -S10). NCCLS 2000. Wayne, Pa.
• 15. Sifaoui F, Varon E, Kitzis MD i inni. In vitro activity of sanfetrinem and affinity for the penicillin- binding proteins of Streptococcus pneumoniae. Antimocrob Agents Chemother 1998; 42: 173-5.
• 16. Singh KV, Coque TM,Murray BE. In vitro activity of the trinem sanfetrinem (GV 104326) against gram-positive organisms. Antimicrob Agents Chemother 1996; 40: 2142-6.
• 17. Spangler SK, Jacobs MR, Appelbaum PC. MIC and time-killstudies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents. Antimicrob Agents Chemother 1997; 41: 148-55.
• 18. Tamura S, Miyazakis, Tateda K i inni. In vivo antibacterial activities of sanfetrinem cilexetil, a new oral triciclic antibiotic. Antimicrob Agents Chemother 1998; 42: 1858-61.
• 19. Wise R, Andrews JM, Brenwald N. In vitro activity of the tricyclic ß-lactam GC 104326. Antimicrob Agents Chemother 1996; 40: 1248-53.
• 20. Wise R, Andrews JM, Da Ros L i inni. A study to determine the pharmacokinetics and inflammatory fluid penetration of two doses of a solid formulation of the hexetil prodrug of a trinem, sanfetrinem (GV 104326). Antimicrob Agents Chemother 1997; 41: 1761-4.